NewGenIvf Operating Cycle from 2010 to 2026

NIVF Stock   0.73  0.15  17.05%   
NewGenIvf Group's Operating Cycle is increasing over the last several years with slightly volatile swings. Operating Cycle is predicted to flatten to 87.03. During the period from 2010 to 2026 NewGenIvf Group Limited Operating Cycle regressed destribution of quarterly values had coefficient of variationof  39.32 and r-value of  0.53. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
150.21
Current Value
87.03
Quarterly Volatility
33.71150766
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check NewGenIvf Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewGenIvf Group's main balance sheet or income statement drivers, such as Interest Income of 8.4 K, Depreciation And Amortization of 216.5 K or Interest Expense of 940.2 K, as well as many indicators such as Price To Sales Ratio of 27.82, Dividend Yield of 0.0 or Days Sales Outstanding of 80.98. NewGenIvf financial statements analysis is a perfect complement when working with NewGenIvf Group Valuation or Volatility modules.
  
Build AI portfolio with NewGenIvf Stock
Check out the analysis of NewGenIvf Group Correlation against competitors.
The Operating Cycle trend for NewGenIvf Group Limited offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether NewGenIvf Group is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest NewGenIvf Group's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of NewGenIvf Group Limited over the last few years. It is NewGenIvf Group's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewGenIvf Group's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

NewGenIvf Operating Cycle Regression Statistics

Arithmetic Mean85.74
Geometric Mean81.05
Coefficient Of Variation39.32
Mean Deviation24.45
Median71.38
Standard Deviation33.71
Sample Variance1,136
Range117
R-Value0.53
Mean Square Error870.80
R-Squared0.28
Significance0.03
Slope3.54
Total Sum of Squares18,183

NewGenIvf Operating Cycle History

2026 87.03
2025 150.21
2024 166.9
2023 50.27
2022 146.6

About NewGenIvf Group Financial Statements

NewGenIvf Group stakeholders use historical fundamental indicators, such as NewGenIvf Group's Operating Cycle, to determine how well the company is positioned to perform in the future. Although NewGenIvf Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in NewGenIvf Group's assets and liabilities are reflected in the revenues and expenses on NewGenIvf Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NewGenIvf Group Limited. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 150.21  87.03 

Currently Active Assets on Macroaxis

When determining whether NewGenIvf Group is a strong investment it is important to analyze NewGenIvf Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NewGenIvf Group's future performance. For an informed investment choice regarding NewGenIvf Stock, refer to the following important reports:
Check out the analysis of NewGenIvf Group Correlation against competitors.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Can Health Care Providers & Services industry sustain growth momentum? Does NewGenIvf have expansion opportunities? Factors like these will boost the valuation of NewGenIvf Group. Anticipated expansion of NewGenIvf directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating NewGenIvf Group demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
4.2 K
Revenue Per Share
101.576
Quarterly Revenue Growth
(0.13)
Return On Assets
(0.23)
Return On Equity
1.6054
Understanding NewGenIvf Group requires distinguishing between market price and book value, where the latter reflects NewGenIvf's accounting equity. The concept of intrinsic value - what NewGenIvf Group's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push NewGenIvf Group's price substantially above or below its fundamental value.
It's important to distinguish between NewGenIvf Group's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewGenIvf Group should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NewGenIvf Group's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.